Sinocare Q3 2025 revenue up, but net profit falls sharply

Sinocare reported a 13.40% increase in Q3 2025 operating revenue to 1,189,603,867.45 yuan. However, net profit attributable to shareholders declined by 47.55% to 30,348,664.34 yuan, with non-recurring items further impacting profitability. Year-to-date operating revenue reached 3,453,271,477.26 yuan, an 8.52% increase, while year-to-date net profit attributable to shareholders decreased by 17.36% to 211,003,372.35 yuan.

Significant balance sheet changes include a 100.51% surge in transactional financial assets to 220,558,193.25 yuan, primarily due to increased trust wealth product purchases. Other current assets also saw a substantial 108.21% increase to 113,935,315.68 yuan. The company’s total assets rose by 2.47% to 6,248,447,592.06 yuan compared to the previous year.

Cash flow from operating activities increased by 33.25% year-to-date, reaching 537,228,973.66 yuan. Noteworthy legal developments include a cross-licensing and settlement agreement with Roche, resulting in a net payment of $19 million, and a temporary injunction against Sinocare in a patent dispute with Abbott in Europe.